Helix BioPharma awarded U.S. Patent for DOS47 adjunct chemotherapy applications

    AURORA, ON, Sept. 17 /CNW/ - Helix BioPharma Corp. (TSX: HBP/Frankfurt:
WKN 918864) announced today the issuance of its second DOS47 patent (U.S.
Patent No. 7,264,800) from the United States Patent & Trademark Office,
describing a method and composition for combining targeted DOS47 therapeutics
with weakly basic chemotherapeutic drugs in adjunct treatment applications.
    "This patent offers a significant extension to Helix's DOS47 intellectual
property position, opening up the possibility for expanded commercial
opportunities," said Dr. Donald H. Segal, President and CEO of Helix. "We
believe there is significant market potential to combine DOS47-based
therapeutics with certain chemotherapeutic drugs in so-called adjunct regimens
because DOS47 therapy is designed to counteract tumor acidity. Tumor acidity
is a property that otherwise makes it difficult for weakly basic
chemotherapeutics to penetrate cancer cells and function effectively."
    With the granting of this second DOS47 patent, Helix now has patent
protection covering the use of targeted DOS47-based therapeutics alone and in
certain combined chemotherapy applications. Moving forward, the Company
intends to pursue the development of DOS47 therapies for both applications,
with a view to maximizing its DOS47 commercialization potential.
    At present, Helix is focused on the development of its first DOS47-based
cancer therapeutic ("L-DOS47") which specifically targets lung adenocarcinoma.
Helix has previously presented scientific findings which demonstrated the
ability of L-DOS47 to destroy lung cancer cells alone and synergistically with
selected chemotherapeutic compounds. Helix continues to advance its
manufacturing and preclinical development programs with a view to phase I
human clinical testing. With this newly issued patent, the Company is
well-positioned to potentially broaden its late stage clinical development
program to include both monotherapy and combined chemotherapy applications for

    About L-DOS47

    L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody, to form a potential new targeted drug
product for the treatment of adenocarcinoma of the lung, the most common form
of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer
effect. It is based upon a naturally occurring enzyme called urease that
essentially reverses the urea cycle by breaking down urea into metabolites
that include ammonia and hydroxyl ions. By doing so at the site of cancerous
tissues in the body, L-DOS47 is believed to modify the microenvironmental
conditions of lung cancer cells in a manner that leads to their death. Among
these theorized effects, L-DOS47 is believed to stimulate an increase in the
pH of the microenvironment surrounding the cancerous cells, effectively
reversing the acidic extra-cellular conditions that are known to be necessary
for cancer cell survival. As well, the local production of ammonia at the site
of cancerous tissues is thought to readily diffuse into the cancer cells to
exert a potent cytotoxic effect by interfering with their critical metabolic
functions. By inducing an alkalizing effect locally at the tumor site, L-DOS47
and other targeted DOS47-based cancer therapeutics may also promote enhanced
cancer cell uptake of weakly basic chemotherapeutic compounds for more
efficient and effective chemotherapeutic action.

    About Helix BioPharma Corp.

    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b, for the treatment of conditions caused by the human
papilloma virus, and its novel L-DOS47 new drug product candidate for the
treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock
Exchange under the ticker symbol "HBP".

    The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this News
Release. This News Release contains certain forward-looking statements and
information regarding Helix's DOS47 drug development program. Forward-looking
statements and information can be identified by the use of forward-looking
terminology such as "possibility", "opportunities", "we believe", "potential",
"is designed to", "moving forward", "intends", "to pursue", "with a view to",
"continue", "is believed", "may", "will", "theorized", or variations thereon
or comparable terminology referring to future events or results. Forward
looking statements and information are statements and information about the
future and are inherently uncertain, and Helix's actual results could differ
materially from those anticipated in these forward-looking statements as a
result of numerous factors, including without limitation, uncertainty whether
L-DOS47 will be developed successfully as a drug or at all; uncertainty
whether DOS47 will be developed as a therapeutic for any other cancers; the
risk that the U.S. patents referred to in this News Release may be challenged
and that the patents, or a portion of them, may subsequently be struck down;
uncertainty whether L-DOS47 or any other DOS47-based cancer therapeutic in an
adjunct regimen with other chemotherapeutics will be effective or successfully
commercialized; the need to partner with a maker of a weakly basic
chemotherapeutic to be able to form an adjunct regimen, which is not assured;
research & development risks, including the risk that early R&D results may
not be repeated in later R&D; the risk of technical obsolescence; the need for
regulatory approvals, which may not be obtained in a timely matter or at all;
the need for clinical trials, the occurrence and success of which cannot be
assured; intellectual property risks; the need to manufacture to regulatory
standards and risks inherent in upscaling; marketing and partnership/strategic
alliance risks; the effect of competition; Helix's need for additional future
capital, which may not be available in a timely manner or at all, as well as a
description of other risks and uncertainties affecting Helix and its business,
as contained in Helix's latest Annual Information Form and other filings with
the Canadian Securities Regulatory Authorities at www.sedar.com, any of which
could cause actual results to vary materially from current results or Helix's
anticipated future results. Forward-looking statements and information are
based on the beliefs, opinions and expectations of Helix's management at the
time they are made, and Helix does not assume any obligation to update any
forward-looking statement or information should those beliefs, opinions or
expectations, or other circumstances change.

For further information:

For further information: Investor Relations, Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416)
815-0080, Email: cbessant@equicomgroup.com; Media Relations, Benjamin
Carmichael, Russo Partners LLC, Tel: (212) 845-4242, Fax: (212) 845-4260,
Email: benjamin.carmichael@russopartnersllc.com, www.russopartnersllc.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890